Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

100923

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Accident and Emergency Departments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many children under the age of five were taken by their parents to accident and emergency departments for treatment in 2012 and 2013.
tabling member printed	Baroness Manzoor
uin	HL2391
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>This information is not available in the format requested.</p><p> </p><p><strong> </strong></p><p> </p><p>In the following table, we have provided information concerning the number of accident and emergency attendances<sup>1</sup> (excluding planned attendances) for children aged under five by arrival mode, 2012-13 to 2013-14<sup>2</sup> (provisional data)<sup>3</sup>.</p><p> </p><p> </p><p> </p><p>Please be aware that data for 2013-14 is provisional and is therefore, subject to change.</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td><p>Arrival mode</p></td><td><p>2012-13</p></td><td><p>2013-14 (provisional)</p></td></tr><tr><td><p>Brought in by ambulance (including helicopter/air ambulance)</p></td><td><p>220,277</p></td><td><p>223,571</p></td></tr><tr><td><p>Other</p></td><td><p>1,572,518</p></td><td><p>1,511,042</p></td></tr><tr><td><p>Not known</p></td><td><p>21,296</p></td><td><p>36,840</p></td></tr><tr><td><p>Total</p></td><td><p>1,814,091</p></td><td><p>1,771,453</p></td></tr></tbody></table><p> </p><p>Activity in English NHS Hospitals and English NHS commissioned activity in the independent sector</p><p> </p><p><em>Source:</em> Hospital Episode Statistics (HES), Health and Social Care Information Centre<sup>4 </sup></p><p> </p><p><strong> </strong></p><p> </p><p><em>Notes:</em></p><p> </p><p>1. HES is not the official source of total A&amp;E activity, this is the NHS England situation reports collection:</p><p> </p><p> </p><p> </p><p>http://www.england.nhs.uk/statistics/statistical-work-areas/ae-waiting-times-and-activity/</p><p> </p><p> </p><p> </p><p>However, HES permits further analysis of A&amp;E activity as there are a range of data items by which HES can be analysed.</p><p> </p><p> </p><p> </p><p>2. HES figures are available from 2007-08 onwards. Changes to the figures over time need to be interpreted in the context of improvements in data quality and coverage and changes in National Health Service practice. For example, changes in activity may be due to changes in the provision of care.</p><p> </p><p> </p><p> </p><p>3. The data is provisional and may be incomplete or contain errors for which no adjustments have yet been made. Counts produced from provisional data are likely to be lower than those generated for the same period in the final dataset. This shortfall will be most pronounced in the final month of the latest period, i.e. November from the (month 9) April to November extract. It is also probable that clinical data are not complete, which may in particular affect the last two months of any given period. There may also be errors due to coding inconsistencies that have not yet been investigated and corrected.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>4. Hospital Episode Statistics (HES) are compiled from data sent by more than 300 NHS trusts and primary care trusts (PCTs) in England and from some independent sector organisations for activity commissioned by the English NHS. Health and Social Care Information Centre liaises closely with these organisations to encourage submission of complete and valid data and seeks to minimise inaccuracies. While this brings about improvement over time, some shortcomings remain.</p><p> </p><p> </p><p> </p> answering member printed Earl Howe question first answered 30/10/2014 12:00:01 answering member 2000 label Biography information for Earl Howe
tabling member	4289 label Biography information for Baroness Manzoor

100623

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Cost Effectiveness
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether the "Nicholson Challenge" still operates within the National Health Service; if so, what efficiency savings have been identified to date; and, if not, why not.
tabling member printed	Lord Sharkey
uin	HL2354
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>The 2010 Spending Review protected health funding in real terms. However, in order to continue to meet rising demands while improving services, it was estimated that up to £20 billion of efficiency savings would be required over the four years from 2011-12 to 2014-15.</p><p> </p><p> </p><p> </p><p>The National Health Service response to this challenge was organised through the Quality, Innovation, Productivity and Prevention (QIPP) initiative, also known colloquially as the ‘Nicholson challenge’ after Sir David Nicholson, who was Chief Executive of the NHS at the time that QIPP originated.</p><p> </p><p> </p><p> </p><p>The NHS is on track to deliver up to £20 billion efficiency savings, having reported around £15 billion of efficiencies in the first three years, all of which will be reinvested into frontline care.</p><p> </p> answering member printed Earl Howe question first answered 30/10/2014 12:11:13 answering member 2000 label Biography information for Earl Howe
tabling member	4196 label Biography information for Lord Sharkey

100716

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the Risk Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211709
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211707 211708 211710 question first answered 30/10/2014 16:13:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100717

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the Impact Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211710
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211707 211708 211709 question first answered 30/10/2014 16:13:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100718

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the next annual report on Research and Development Work Relating to Assistive Technology.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211707
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211708 211709 211710 question first answered 30/10/2014 16:13:23 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100719

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Assistive Technology: Annual Reports
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the next annual report on Research and Development Work Relating to Assistive Technology to be laid before parliament.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	211708
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 211707 211709 211710 question first answered 30/10/2014 16:13:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

100720

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Osteoporosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211731
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.</p><p> </p><p> </p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>6.6 Drugs affecting bone metabolism</p><p> </p><p>9.5.1.1 Calcium supplements</p><p> </p><p>9.6 Vitamins (colecalciferol and ergocalciferol only)</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of osteoporosis, England<sup>1</sup></p></td></tr><tr><td><p>Drug Name<sup>2</sup></p></td><td colspan="5"><p>Primary Care</p><p>(£ million)</p></td><td colspan="5"><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>Year</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Alendronic Acid</p></td><td><p>14.0</p></td><td><p>12.4</p></td><td><p>10.8</p></td><td><p>9.7</p></td><td><p>8.9</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Alendronic Acid and Colecalciferol</p></td><td><p>1.4</p></td><td><p>1.2</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Calcitonin (Salmon)</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Calcium</p></td><td><p>4.2</p></td><td><p>4.7</p></td><td><p>4.5</p></td><td><p>3.7</p></td><td><p>3.3</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Calcium and Colecalciferol</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.2</p></td><td><p>2.2</p></td><td><p>2.1</p></td><td><p>2.2</p></td><td><p>2.3</p></td></tr><tr><td><p>Clodronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.9</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Colecalciferol</p></td><td><p>42.4</p></td><td><p>48.3</p></td><td><p>58.5</p></td><td><p>67.6</p></td><td><p>75.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.4</p></td><td><p>1.2</p></td></tr><tr><td><p>Denosumab</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td><td><p>1.9</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.9</p></td><td><p>2.3</p></td><td><p>9.9</p></td></tr><tr><td><p>Disodium Etidronate</p></td><td><p>1.3</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Ergocalciferol</p></td><td><p>4.3</p></td><td><p>7.8</p></td><td><p>8.0</p></td><td><p>7.0</p></td><td><p>6.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td></tr><tr><td><p>Ibandronic Acid</p></td><td><p>12.1</p></td><td><p>12.1</p></td><td><p>11.4</p></td><td><p>10.6</p></td><td><p>4.7</p></td><td><p>2.1</p></td><td><p>2.0</p></td><td><p>1.8</p></td><td><p>1.5</p></td><td><p>0.9</p></td></tr><tr><td><p>Pamidronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>9.6</p></td><td><p>9.1</p></td><td><p>9.4</p></td><td><p>9.4</p></td><td><p>8.7</p></td></tr><tr><td><p>Risedronate Sodium and Risedronate Acid</p></td><td><p>27.9</p></td><td><p>22.9</p></td><td><p>11.6</p></td><td><p>2.4</p></td><td><p>2.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Sodium Clodronate</p></td><td><p>7.8</p></td><td><p>7.2</p></td><td><p>6.3</p></td><td><p>5.5</p></td><td><p>4.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Strontium Ranelate</p></td><td><p>7.0</p></td><td><p>7.8</p></td><td><p>9.0</p></td><td><p>9.2</p></td><td><p>7.3</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>Teriparatide</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>2.7</p></td><td><p>2.8</p></td><td><p>2.7</p></td><td><p>3.1</p></td><td><p>3.2</p></td></tr><tr><td><p>Zoledronic Acid</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>16.7</p></td><td><p>18.0</p></td><td><p>20.9</p></td><td><p>23.7</p></td><td><p>25.7</p></td></tr><tr><td><p>Other Calcium Supplement Preps</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Other drugs<sup>3</sup></p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td></tr><tr><td><p>TOTAL</p></td><td><p>123.8</p></td><td><p>126.8</p></td><td><p>123.4</p></td><td><p>119.1</p></td><td><p>115.4</p></td><td><p>39.6</p></td><td><p>39.6</p></td><td><p>42.3</p></td><td><p>46.2</p></td><td><p>55.0</p></td></tr></tbody></table><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> The patent for some of these drugs may have expired during this period.</p><p> </p><p><sup>3</sup> “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.</p><p> </p><p> </p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 30/10/2014 16:09:20 answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100724

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much has been spent on the prescription of drugs for the treatment of motor neurone disease in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211727
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>Information on National Health Service expenditure on drugs for the treatment of motor neurone disease in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Riluzole is the only drug defined in the British National Formulary as being used for the treatment of motor neurone disease</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Cost of riluzole, England<sup>1</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary Care</p><p>(£ million)</p></td><td><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>2009</p></td><td><p>3.8</p></td><td><p>1.2</p></td></tr><tr><td><p>2010</p></td><td><p>4.9</p></td><td><p>1.4</p></td></tr><tr><td><p>2011</p></td><td><p>5.5</p></td><td><p>1.4</p></td></tr><tr><td><p>2012</p></td><td><p>5.8</p></td><td><p>1.5</p></td></tr><tr><td><p>2013<sup>2</sup></p></td><td><p>2.3</p></td><td><p>1.0</p></td></tr></tbody></table><p> </p><p><sup>1</sup> Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2 </sup>The patent for riluzole expired in the first quarter of 2013.</p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since a drug could be prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which it may have been prescribed. The information provided may therefore include costs from the prescribing of the drug for conditions other than for motor neurone disease.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 30/10/2014 16:04:31 answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100727

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Members: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he intends to reply to the letter to him dated 16 September 2014 from the right hon. Member for Manchester, Gorton with regard to Ms S Whyatt.
tabling member constituency	Manchester, Gorton
tabling member printed	Sir Gerald Kaufman
uin	211689
answer	answer is ministerial correction date of answer 30/10/2014 answer text <p>I replied to the Rt. hon. Member’s letter of 16 September 2014 on 8 October 2014.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 30/10/2014 16:00:56 answering member 1439 label Biography information for Norman Lamb
tabling member	451 label Biography information for Sir Gerald Kaufman